The erythropoietin analogue darbepoetin alfa reduced the need for transfusions, increased hemoglobin concentrations, and decreased fatigue in patients with lung cancer, according to the results of a double-blind phase III trial reported in the Aug. 21 issue of the Journal of the National Cancer Institute.
“Patients with chemotherapy-associated anemia can safely and effectively be treated with weekly darbepoetin alfa therapy,” write Johan Vansteenkiste, MD, PhD, of the University Hospital Gasthuisberg in Leuven, Belgium, and colleagues.
“Patients receiving darbepoetin alfa did not appear to have any untoward effect in disease outcome and did not develop antibodies to the drug.” In this multicenter study, 320 anemic lung cancer patients with hemoglobin
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!